AcquisitionOther

ARENA PHARMACEUTICALS INC acquired target

Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.

Deal tape row

ARENA PHARMACEUTICALS INC -> target · $100

Arena’s portfolio includes diverse and promising development-stage therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator currently in development for a

Open source record (SEC) ↗